What is Retatrutide? A Clinical Overview of the Investigational Triple Agonist

Important: investigational medicine notice. Retatrutide is an investigational medication. It has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or any other regulator, and it cannot be legally prescribed, dispensed or sold in the UK outside of an authorised clinical trial. This article is for information only. It is not medical advice and is not a recommendation to seek, request or use retatrutide. If you are considering weight-management medication, speak to your GP or a regulated UK prescriber about MHRA-approved options.

Retatrutide (development code LY3437943) is an investigational once-weekly injectable medicine being developed by Eli Lilly and Company for chronic weight management and related metabolic conditions. It belongs to the broader family of incretin-based therapies that includes semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), but it differs from every medicine currently approved in the UK in one important respect: it activates three hormone receptors at the same time rather than one or two.

This article gives a measured, evidence-based overview of what retatrutide is, where it sits in the obesity pharmacotherapy landscape, and what is — and is not — currently known about it. Later articles in this series cover the mechanism of action, the published trial data, the side-effect profile, and the UK regulatory position in more detail.

What kind of medicine is retatrutide?

Retatrutide is described in the published clinical literature as a "triple hormone receptor agonist". In plain English, it is a single molecule designed to activate three different receptors in the body simultaneously:

The glucagon-like peptide-1 (GLP-1) receptor — the same receptor targeted by semaglutide.
The glucose-dependent insulinotropic polypeptide (GIP) receptor — one of the two receptors targeted by tirzepatide.
The glucagon receptor — which is not targeted by any currently MHRA-approved weight-management medicine.

The published Phase 2 trial in the New England Journal of Medicine describes retatrutide as "an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors". The hypothesis underpinning the molecule is that combining these three receptor activities in one drug may produce greater metabolic effects than activating one or two of them in isolation. Whether that hypothesis holds up in the long term, and across larger and more diverse populations, is what the ongoing Phase 3 programme is designed to test.

A more detailed explanation of how each of these three hormone systems contributes to appetite, blood-sugar control and energy expenditure is covered in the next article in this series, How Retatrutide Works.

How is retatrutide administered in trials?

In the published and reported clinical trials, retatrutide has been given as a once-weekly subcutaneous (under-the-skin) injection. Trial participants started at a low dose and were titrated upwards over several weeks — a familiar pattern from existing GLP-1 medicines, designed to reduce the gastrointestinal side effects that tend to appear when these medicines are introduced too quickly.

The Phase 3 TRIUMPH programme has tested five doses — 2 mg, 4 mg, 6 mg, 9 mg and 12 mg — with all participants starting at 2 mg once weekly and escalating from there. These are trial protocols only. There is no UK Summary of Product Characteristics (SmPC) for retatrutide because no UK marketing authorisation exists, and the doses and titration schedule that would apply if and when the medicine is approved are not yet determined.

What conditions is retatrutide being studied for?

Eli Lilly's published clinical trial programme — branded TRIUMPH — is studying retatrutide across a range of indications, not just obesity in isolation. According to Lilly's investor releases and the public clinical-trials registry, the programme includes studies in:

Obesity and overweight with at least one weight-related health condition.
Type 2 diabetes (including the TRANSCEND-T2D-1 Phase 3 trial, which reported positive topline results in March 2026).
Obesity or overweight with knee osteoarthritis (TRIUMPH-4, which reported topline results in December 2025).
Obstructive sleep apnoea in adults with obesity.
Chronic low back pain in adults with obesity.
Cardiovascular and renal outcomes.
Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH).

This breadth reflects a broader trend in obesity pharmacotherapy: medicines in this class are increasingly being studied not only for weight reduction itself, but for the secondary health benefits — cardiovascular, metabolic, musculoskeletal and hepatic — that meaningful weight reduction can support. None of these indications is a guarantee of future approval; they are areas under investigation.

How does retatrutide compare with what is already approved in the UK?

It is important to be precise here. The medicines currently approved by the MHRA for weight management in adults in the UK include semaglutide 2.4 mg (Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda), orlistat, and naltrexone/bupropion (Mysimba). NICE has issued technology appraisal guidance for semaglutide (TA875) and tirzepatide (TA1026) within specialist weight-management services. Retatrutide is on none of these lists. It is an investigational medicine that has not yet completed Phase 3 trials in full, has not been submitted to the MHRA for review, and has no marketing authorisation, no SmPC, and no NICE appraisal.

What the published evidence does suggest is that retatrutide is targeting a larger magnitude of weight reduction than currently approved medicines. The Phase 2 trial reported a mean weight reduction of 24.2% at 48 weeks on the 12 mg dose. The TRIUMPH-4 Phase 3 topline reported a mean reduction of 28.7% at 68 weeks on the 12 mg dose in adults with obesity and knee osteoarthritis. By comparison, the Phase 3 STEP 1 trial of semaglutide 2.4 mg reported approximately 14.9% mean weight reduction at 68 weeks, and the SURMOUNT-1 trial of tirzepatide reported up to 22.5% at 72 weeks.

These cross-trial comparisons should be read with caution. The populations enrolled, the comparator arms, the duration of treatment and the statistical methods used differ between studies. A direct head-to-head trial between retatrutide and a currently approved medicine has not yet been published. A more detailed discussion of how retatrutide compares with Mounjaro and Wegovy is covered in later articles in this series.

What is the current UK status of retatrutide?

As of the date of this article, retatrutide has:

No MHRA marketing authorisation — it is not approved for use in the UK for any indication.
No UK SmPC — there is no UK product label specifying licensed doses, indications, contraindications or warnings.
No NICE technology appraisal — NICE cannot appraise a medicine that has not received marketing authorisation.
No legal route to private prescription, NHS prescription, or pharmacy supply in the UK, outside of authorised clinical trials.

The MHRA has carried out enforcement actions against UK facilities producing unlicensed retatrutide pens — including a record seizure in Northampton in October 2025 and a further enforcement operation in Lincolnshire in February 2026. The MHRA has been explicit in its public communications that any product sold in the UK as retatrutide outside of an authorised clinical trial is unlicensed, and that taking such products carries serious health risks. This is covered in more detail in a separate article in this series, Unlicensed Retatrutide in the UK: What the MHRA Has Said and Why It Matters.

When might retatrutide be available in the UK?

Any answer to this question is, at present, an estimate. The TRIUMPH Phase 3 programme is ongoing and additional trial readouts are expected throughout 2026. Eli Lilly has not publicly announced an MHRA submission date.

Following the regulatory pattern of comparable medicines — MHRA authorisation for Wegovy in September 2021 followed by NICE TA875 in March 2023, and MHRA authorisation for Mounjaro for weight management in November 2023 followed by NICE TA1026 in December 2024 — it would be reasonable to expect that any future MHRA approval for retatrutide would follow Phase 3 completion by some months, and any NHS access would follow MHRA approval by a further period of NICE technology appraisal. Specific dates are not currently determinable, and any source claiming to know a confirmed UK launch date should be treated with scepticism. We will update this article as the regulatory position changes.

The bottom line

Retatrutide is an investigational triple hormone receptor agonist that has produced larger weight reductions in published trials than any currently MHRA-approved weight-loss medicine. It is not approved in the UK, it cannot be legally prescribed or supplied here outside a clinical trial, and the published data — while promising — is still emerging. The Phase 3 programme is ongoing, and the safety and efficacy picture will continue to develop.

If you are considering weight-management medication, your starting point should be a conversation with your GP or a regulated UK prescriber. The medicines they can legally prescribe in the UK today are the MHRA-approved options listed above — not retatrutide.

Sources and further reading

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514–526. DOI: 10.1056/NEJMoa2301972.
Eli Lilly investor release, 11 December 2025: Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4 topline).
Eli Lilly investor release, 19 March 2026: Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes (TRANSCEND-T2D-1 topline).
UK Government / MHRA: GLP-1 medicines for weight loss and diabetes: what you need to know (GOV.UK publication).
MHRA news release, 24 October 2025: MHRA smashes major illicit weight loss medicine production facility in record seizure.
MHRA news release, 25 February 2026: MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines.
NICE technology appraisal TA875 (semaglutide 2.4 mg for managing overweight and obesity).
NICE technology appraisal TA1026 (tirzepatide for managing overweight and obesity).